Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus standard chemotherapy vs standard chemotherapy for first-line metastatic colorectal cancer
jRCT2080223856Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in metastatic colon cancer (mCRC) comparing Nivolumab plus standard-of-care chemotherapy with Standard-of-care chemotherapy (2 arms). Started Apr 2018; status: completed.
02
Drugs
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080223856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223856.